Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Study on Bortezomib and Low-Dose Dexamethasone With or Without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma

NCT00813150 is registered in ClinicalTrials.gov with Janssen-Cilag G.m.b.H as lead sponsor.

NCT NCT00813150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00813150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Study on Bortezomib and Low-Dose Dexamethasone With or Without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma
Lead sponsor
Janssen-Cilag G.m.b.H
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2009
Completion date
January 31, 2013
Enrollment
96 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma